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ReprogramMyocardial infarction (MI) is one of the leading causes of morbidity and mortality world-wide. Whether en-
dogenous repair and regenerative ability could be augmented by drug administration is an important issue
for generation of novel therapeutic approach. Recently it was reported that in mice pretreated with thymosin
beta 4 (TB4) and subsequently subjected to experimental MI, a subset of epicardial cells differentiated into
cardiomyocytes. In clinical settings, epicardial priming with TB4 prior to MI is impractical. Here we tested
if TB4 treatment after MI could reprogram epicardium into cardiomyocytes and augment the epicardium's in-
jury response. Using epicardium genetic lineage trace line Wt1CreERT2/+ and double reporter line
Rosa26mTmG/+, we found post-MI TB4 treatment signiﬁcantly increased the thickness of epicardium and coro-
nary capillary density. However, epicardium-derived cells did not adopt cardiomyocyte fate, nor did theymigrate
intomyocardium to become coronary endothelial cells. Our result thus indicates that TB4 treatment afterMIdoes
not alter epicardial cell fate to include the cardiomyocyte lineage, providing both cautions and insights for the full
exploration of the potential beneﬁts of TB4 in the clinical settings. This article is part of a Special Issue entitled
‘Possible Editorial’.nghai 200031, China. Tel.: +86
wood Ave, Boston, MA, 02115,
@enders.tch.harvard.edu
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Myocardial infarction (MI) is a one of the leading cause of mortality
and morbidity. As a result of inadequate myocardial perfusion, billions
of cardiomyocytes are lost in human hearts after an acute myocardial
infarction [1,2]. Recent work showed that extracardiac or intracardiac
progenitor cells have beneﬁcial effects after MI, suggesting a potential
therapeutic role for regenerative approaches to heart failure [3]. How-
ever, stem cell transplantation approaches still face numerous hurdles,
including graft survival, effective functional integration with existing
myocardium, immune responses to non-autologous donor cells, and
uncertain long term beneﬁts [4]. An attractive alternative approach is
to augment the regenerative capacity of resident cardiac progenitor
cells. Success hinges on identiﬁcation of suitable cardiac progenitorsresident in the adult heart, and uncovering factors and pathways that
increase the regenerative ability of these progenitors.
One potential progenitor population is located within the epicar-
dium. This single layer of epithelial cells is pivotal for normal heart
development, as it provides both mesenchymal cells (derived
through an epithelial to mesenchymal transition) and paracrine fac-
tors necessary for growth of the myocardium and the coronary vascu-
lature [5]. Using genetic fate mapping approaches, we and others
found that epicardium cells contribute to ﬁbroblast, vascular smooth
muscle, endothelial, and cardiomyocyte lineages during heart develop-
ment [6,7]. However, the epicardial origin of cardiomyocytes during
heart development remains controversial [8,9].
While the role of epicardium in heart development has been in-
tensely studied, relatively little is known about epicardial function
in the normal and injured adult heart. In adult zebraﬁsh, amputa-
tion of the myocardial apex reactivated fetal epicardial genes.
The epicardium appeared to be intimately involved in the regener-
ative response [10,11], although there was no direct epicardial
contribution to the cardiomyocyte lineage in zebraﬁsh hearts
[12]. Recently, we showed that MI markedly expanded the adult
murine epicardium and reactivated expression of fetal epicardial
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jury could be an attractive approach for promoting cardiac repair
and regeneration.
Thymosin beta 4 (TB4), a 43 amino acid actin monomer-binding
peptide, plays an important role in normal heart development, pro-
moting myocardial growth, coronary vasculogenesis, and epicardial
integrity. Administration of TB4 promoted cardiac repair in a murine
MI model [14], and TB4 has been undergoing clinical trials as a treat-
ment for MI (www.clinicaltrials.gov, NCT00743769). In the murine
model, TB4 reduced cardiomyocyte apoptosis and promote cardiac
function recovery after MI [14]. While TB4 appears to have beneﬁcial
activity in promoting myocardial repair, the mechanisms of action re-
main uncertain. At least one site of TB4 action is the epicardium, as
TB4-stimulated epicardium expanded markedly in vitro and in vivo
[15,16]. In explant culture, TB4 also reactivated fetal epicardial proper-
ties, including restoring the capacity of adult epicardial explants to
generate mesenchymal cells that differentiate into ﬁbroblast, endothe-
lial cell, and smooth muscle cell fates [16]. However whether TB4 ad-
ministered after MI inﬂuences epicardial differentiation programs has
not been directly investigated in vivo. Here we addressed this question
using genetic lineage tracing in a murine model.
2. Methods
An expanded Methods section is available in the data supplement
and includes detailed information regarding the following experi-
mental procedures: myocardium infarction, epicardial cell isolation
and culture, quantitative RT-PCR, immunostaining and immunohisto-
chemistry, and statistical analysis.
3. Results
To begin to better understand potential roles of TB4 in myocardial
repair, we measured TB4 expression in the postnatal heart by qRTPCR
and immunohistochemistry. MI signiﬁcantly upregulated TB4 expres-
sion in the heart, with expression peaking 5 days following infarction
(Supplementary Fig. 1A). At 1 week post MI, immunostaining indicated
that the epicardium strongly expressed TB4 (Supplementary Fig. 1B).
Enrichment of TB4 in epicardium and its derivatives was conﬁrmed in
both fetal and post-MI heart by qRTPCR of FACS-puriﬁed cells isolated
fromWt1CreERT2/±;Rosa26mTmG/±mice, inwhichGFP indelibly labels epi-
cardial cells and their descendants (Supplementary Figs. 1C–E) [13]. For
simplicity, in this report we refer to these GFP-labeled cells, composed
of epicardium and its derivatives, as epicardium-derived cells
(EPDCs), and we use the term ‘epicardial layer’ to refer to the region
of the adult heart overlying the myocardium that contains these
EPDCs. In conjunction with the beneﬁcial effects of exogenous TB4 in
the MI model [14], these data suggest that native, epicardium-
secreted TB4might also protect and promote repair and vascularization
of the underlying myocardium.
Next, we investigated the effect of exogenous TB4 administration
on the myocardial injury response, using a genetic lineage tracing ap-
proach to evaluate the effect of TB4 treatment on epicardial cell fate
in vivo. Previous work indicated that TB4 administered after MI inﬂu-
enced epicardial activity [15], but the effect of TB4 on epicardial cell
fate after MI has not been investigated using direct genetic lineage
tracing approaches. We addressed this point using the Wt1CreERT2/+;
Rosa26mTmG/+ system to follow the fate of EPDCs through their indelible
GFP label. We inducedMI in these mice, then treated with TB4 each day
after MI for 1 week, and analyzed the fate of GFP-expressing EPDCs at
2 weeks post-MI. We conﬁrmed that TB4 was effective in our hands by
reproducing the previously reported beneﬁcial effects of TB4 onmyocar-
diumafter infarction [14,17]. Speciﬁcally, as previously reported TB4 sig-
niﬁcantly reduced infarct size, cardiac ﬁbrosis, and cardiomyocyte
apoptosis, and increased vessel density (Supplementary Figs. 2A–C). In-
terestingly, TB4 treatment also augmented thickening of the epicardiallayer that occurs following MI, as determined by immunohistochemis-
try for GFP-labeled EPDCs in Wt1CreERT2/+;Rosa26mTmG/+ mice
(Figs. 1A, B; Supplementary Fig. 3A). Our recent work suggested that
thickening of the epicardial layer, comprised of EPDCs and epicardial
cells, after MI contributes importantly to its secretion of paracrine fac-
tors that mitigate myocardial injury and adverse cardiac remodeling
[13]. Thus, TB4-induced epicardial thickening likely participates in the
salutary effects of TB4. The above result showed that the TB4 in our
models (post-MI) was effective and beneﬁcial in protection for injured
heart.
Given the putative, albeit controversial, capacity of fetal epicardium
to differentiate into cardiomyocytes, we asked if post-MI TB4 treatment
induces cardiomyocyte differentiation from adult epicardium. Using the
GFP lineagemarker, we dissected the fate of epicardium cells by immu-
nostaining TB4-treated infarcted hearts for co-expression of cardiomyo-
cyte, ﬁbroblast, smooth muscle, and endothelial cell markers. Like
control (PBS-treated) MI hearts at 2 week post MI, GFP+ EPDCs in
TB4-treated MI hearts did not migrate into myocardium nor did they
express cardiomyocyte or endothelial cell markers (Figs. 1C, D; Supple-
mentary Figs. 3B, C; data not shown). A subset of EPDCs expressedmyo-
ﬁbroblast/ﬁbroblast or smooth muscle markers smooth muscle actin
alpha (ACTA2), desmin, ﬁbroblast-speciﬁc protein (FSP1), procollagen
alpha1 type I (Pro-Col1a1), heat shock protein 47 (HSP47), collagen III
(ColIII) and discoidin domain receptor 2 (DDR2) (Figs. 1E–I and Supple-
mentary Figs. 2D, E). To conﬁrm these results, we analyzed FACS-
puriﬁed EPDCs from Wt1CreERT2/+;Rosa26mTmG/+ MI hearts treated
with TB4 (Fig. 2A). Strong enrichment of epicardial genes Wt1 and
Tbx18 in the GFP+ population validated the puriﬁcation procedure
(Fig. 2B). Immunostaining of the isolated cells permitted analysis of lin-
eage markers in isolated cells and thereby avoided potential artifacts
from staining of tissue sections. The isolated GFP+ cells expressed epi-
cardial markers WT1 and TBX18, but did not co-express cardiomyocyte
markers cardiac troponin T (TNNT2) or cardiac actinin alpha (ACTN2,
Fig. 2C). In control experiments, TNNT and ACTN2 were readily
stained cells in the GFP− population (data not shown), excluding a
technical staining failure. In accordance with results from tissue sec-
tion staining, a subset of EPDCs differentiated into myoﬁbroblast and
smooth muscle cells (Fig. 2C). EPDCs isolated from PBS-treated mice
adopted a similar set of cell fates, which did not include cardiomyo-
cytes (Fig. 2D).
4. Discussion
Our present work used mouse genetic models to directly show
that TB4 administered after myocardial infarction increased expan-
sion of epicardium and reduced infarct size. Endogenous TB4 was
upregulated in epicardium after MI, suggesting that native TB4 partic-
ipates in the myocardial injury response by promoting epicardial ex-
pansion, reducing myocardial apoptosis, and improving myocardial
vascularization. The epicardial actions of TB4 are likely linked to its
beneﬁcial effects in MI, as thickening of the epicardium layer likely
enhances its production of beneﬁcial paracrine factors [10,13] and
contributes to production of smooth muscle cells and ﬁbroblasts
that may provide mechanical protection as the myocardium thins
due to loss of myocytes after MI.
Our data indicate that TB4 administered post-MI does not mobi-
lize EPDCs so that they cannot migrate into the myocardium like
fetal EPDCs [6,7]. Furthermore, post-MI TB4 did not direct EPDC dif-
ferentiation into cardiomyocytes. This result contrasts with the effect
of TB4 administered prior to MI, where “priming” of epicardium by
TB4 reprogrammed EPDCs so that a subset differentiated into cardio-
myocytes after subsequent MI [18]. Both experiments used clinical
grade TB4 from the same source. Importantly, we also observed the
beneﬁcial effect of TB4 for injury repair after MI, supporting biological
activity of TB4 in our system. Both experiments also employed the
same epicardium speciﬁc inducible Cre line (Wt1CreERT2/±) [4] for
Fig. 1. Reactivated epicardial layer and cell fate after myocardial infarction followed by thymosin β4 (TB4) treatment. After myocardial infarction followed by TB4 or PBS treatment,
Wt1CreERT2/+;Rosa26mTmG/+ hearts were analyzed by immunochemistry. (A, B) Immunostaining for GFP in TB4-treated (A) or PBS-treated (B) heart. GFP marks EPDCs. The GFP+
epicardial layer covering the heart was thicker in the peri-infarct (arrowheads, inset 1) and infarct (arrows, inset 3) regions with TB4 treatment. The epicardial layer remained
thin in the remote (right ventricular) region (inset 2). LV, left ventricle; RV, right ventricle; bar=100 μm. (C) EPDCs (white arrowheads) did not migrate into myocardium or ex-
press cardiomyocyte markers inWt1CreERT2/+;Rosa26mTmG/+ hearts that underwent experimental infarction followed by TB4 treatment. White arrows indicate cardiomyocytes and
white arrowheads indicate EPDCs. White dotted line indicates the border between myocardium and the epicardial layer. Bar=100 μm. (D–I) In infarcted, TB4-treated heart, EPDCs
(GFP+) did not differentiate into coronary endothelial cells, marked by PECAM. A subset of cells expressed smooth muscle actin (ACTA2) or DESMIN, markers of myoﬁbroblast and
smooth muscle cells. Many GFP+ cells also co-expressed ﬁbroblast markers FSP1, Pro-Collagen I and HSP47. Bar=200 μm.
45B. Zhou et al. / Journal of Molecular and Cellular Cardiology 52 (2012) 43–47genetic fate mapping [6]. Thus the lack of cardiomyocyte fate in our
experiment is unlikely due to labeling of different epicardial cell
subpopulations.The principal difference between the experiments was the timing
of TB4 injection, as we administered TB4 following MI, while Smart
and colleagues primed mice by TB4 pretreatment. Myocardial injury
Fig. 2. Non-cardiomyocyte fate of epicardial cells after TB4 injection. (A) FACS isolation of GFP+ EPDCs from Wt1CreERT2/+;Rosa26mTmG/+ hearts treated by LAD ligation followed by
TB4 injection. (B) Quantitative RT-PCR showed highly puriﬁed EPDCs after FACS isolation (n=3). (C) Immunostaining of primary EPDCs isolated from infarcted, TB4-treated hearts
showed co-expression of markers of epicardial cells (WT1, TBX18) and smooth muscle or myoﬁbroblast cells (CNN1, αSMA), but not cardiomyocytes (TNNT2, ACTN2). (D) Immu-
nostaining of primary isolated EPDCs from infarcted, PBS-treated hearts. White bar=50 μm.
46 B. Zhou et al. / Journal of Molecular and Cellular Cardiology 52 (2012) 43–47substantially alters epicardial cell properties and gene expression
[13], and it is possible that these changes impair the ability of TB4
to augment epicardial cell plasticity. Another possibility is thatmyocardial injury disrupts the architecture of an epicardial niche
that is required for nurturing epicardial cells to be reprogrammed.
In clinical practice, it will not be feasible to administer TB4 prior to
47B. Zhou et al. / Journal of Molecular and Cellular Cardiology 52 (2012) 43–47MI. Thus, effective translation of TB4-primed EPDC differentiation
into cardiomyocytes will require understanding why TB4 fails to in-
duce EPDC plasticity when administered following anMI, and the mo-
lecular mechanisms underlying the difference.
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